CELULARITY INC C/WTS 24/05/2026 (TO PUR COM) News

Celularity Data Published in Journal for ImmunoTherapy of Cancer Reveals Benefits of Placental Circulating T Cells for CAR-T Therapy

FLORHAM PARK, N.J., May 14, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a regenerative and cellular medicine company developing placental-derived allogeneic cell therapies and advanced

GlobeNewswire21:15

Celularity Inc. to Host Investor and Analyst Research & Development Day

FLORHAM PARK, N.J., April 22, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a regenerative and cellular medicine company developing placental-derived allogeneic cell therapies and advanced

GlobeNewswireApr 22 20:00

Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing

FLORHAM PARK, N.J., April 19, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) (the "Company"), a regenerative medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial

GlobeNewswireApr 20 05:30

Celularity Abstract "Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials" Accepted at ORS Tendon Conference 2024

Celularity Inc. (Nasdaq: CELU) today announced that its abstract entitled "Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials" was accepted by the Orthopedic Research Society (ORS) Tendon Conference, which will be held from May 30 - June 1, 2024 at the Mayo Clinic in Rochester, MN.

GlobeNewswireApr 19 04:30

Celularity Announces Net Sales Trending Ahead of Expectations for First Quarter 2024; Implements Planned 2024 SG&A Reductions and Manufacturing Ramp for Advanced Biomaterial Products

Expects the First Quarter of 2024 will be the 4th consecutive quarter of both sequential and quarter-on-quarter net sales growth Implements plan to reduce 2024 selling, general & administrative expens

GlobeNewswireApr 15 20:00

Celularity to Present Data Showing Senescent Cell Elimination by Off-the-Shelf Natural Killer Cells Derived From Human Placental Cells

Company Presenting at ASGCT Annual MeetingFLORHAM PARK, N.J., April 08, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ: CELU) ("Celularity"), a biotechnology company developing placental-derived a

GlobeNewswireApr 8 21:00

Celularity Receives Healthcare Common Procedure Coding System (HCPCS) Q Code Approval From the U.S. Centers for Medicare & Medicaid Services for Biovance 3L

Nationally Established Q Code Will Further Support the Use of Biovance 3L by Physicians to Treat Wound Care Patients in Office SettingsFLORHAM PARK, N.J., March 26, 2024 (GLOBE NEWSWIRE) -- Celulari

GlobeNewswireMar 26 21:00

Celularity Submits Request to U.S. FDA for Orphan Drug Designation for PDA-002 Asset Treating Facioscapulohumeral Muscular Dystrophy

FLORHAM PARK, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a regenerative medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial

GlobeNewswireMar 20 21:15

Celularity CEO to Present on Cell Therapy's Potential to Improve Longevity at 2024 ABUNDANCE Summit

FLORHAM PARK, N.J., March 14, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity" or the "Company"), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial

GlobeNewswireMar 14 21:15

Celularity CEO to Present Keynote Address at 2024 Society for Brain Mapping and Therapeutics Annual World Congress

FLORHAM PARK, N.J., March 12, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity" or the "Company"), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial

GlobeNewswireMar 12 21:20

Celularity to Present Data Showing Cancer Tumor Reduction by Off-the-Shelf Cell Therapy Derived From Human Placental Cells

FLORHAM PARK, N.J., March 07, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, announced

GlobeNewswireMar 7 22:35

Trading Halt: Halt Status Updated at 9:00:00 AM ET: Quotation Resumption: News and Resumption Times

Trading Halt: Halt Status Updated at 9:00:00 AM ET: Quotation Resumption: News and Resumption Times

BenzingaFeb 29 22:00

Celularity Announces 1-for-10 Reverse Stock Split

Globe NewswireFeb 24 05:10

Celularity's Tri-layer Decellularized, Dehydrated Human Amniotic Membrane Product Investigated as a Carrier of Induced Pluripotent Stem Cell Derived-Limbal Stem Cells in the Treatment of Severe Ocular Surface Disease

Yahoo FinanceFeb 15 05:05

Celularity Releases CEO Letter to Shareholders

Yahoo FinanceJan 19 02:40

Celularity Inc. (NASDAQ:CELUW) Short Interest Up 19.2% in March

Celularity Inc. (NASDAQ:CELUW – Get Rating) saw a large increase in short interest during the month of March. As of March 15th, there was short interest totalling 8,700 shares, an increase of 19.2% f

Financial News LiveApr 2, 2023 05:31

Short Interest in Celularity Inc. (NASDAQ:CELUW) Declines By 60.1%

Celularity Inc. (NASDAQ:CELUW – Get Rating) was the recipient of a significant decline in short interest in the month of February. As of February 28th, there was short interest totalling 7,300 shares,

kopsourceMar 13, 2023 11:22

Celularity Inc. (NASDAQ:CELUW) Sees Large Growth in Short Interest

Celularity Inc. (NASDAQ:CELUW – Get Rating) was the recipient of a large growth in short interest in February. As of February 15th, there was short interest totalling 18,300 shares, a growth of 190.5

Defense WorldMar 1, 2023 14:53

Celularity Inc. (NASDAQ:CELUW) Short Interest Down 12.5% in January

Celularity Inc. (NASDAQ:CELUW – Get Rating) was the target of a significant decrease in short interest in the month of January. As of January 31st, there was short interest totalling 6,300 shares, a

Financial News LiveFeb 18, 2023 07:31